By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Investigators publish new report on Diabetes. According to news reporting originating in Villeneuve d'Ascq, France, by NewsRx journalists, research stated, "We have previously demonstrated that central apelin is implicated in the control of peripheral glycemia, and its action depends on nutritional (fast versus fed) and physiological (normal versus diabetic) states. An intracerebroventricular (icv) injection of a high dose of apelin, similar to that observed in obese/diabetic mice, increase fasted glycemia, suggesting (i) that apelin contributes to the establishment of a diabetic state, and (ii) the existence of a hypothalamic to liver axis."
The news reporters obtained a quote from the research from the University of Lille, "Using pharmacological, genetic, and nutritional approaches, we aim at unraveling this system of regulation by identifying the hypothalamic molecular actors that trigger the apelin effect on liver glucose metabolism and glycemia. We show that icv apelin injection stimulates liver glycogenolysis and gluconeogenesis via an over-activation of the sympathetic nervous system (SNS), leading to fasted hyperglycemia. The effect of central apelin on liver function is dependent of an increased production of hypothalamic reactive oxygen species (ROS). These data are strengthened by experiments using lentiviral vector-mediated over-expression of apelin in hypothalamus of mice that present over-activation of SNS associated to an increase in hepatic glucose production. Finally, we report that mice fed a high-fat diet present major alterations of hypothalamic apelin/ROS signaling, leading to activation of glycogenolysis. Innovation/Conclusion: These data bring compelling evidence that hypothalamic apelin is one master switch that participates in the onset of diabetes by directly acting on liver function."
According to the news reporters, the research concluded: "Our data support the idea that hypothalamic apelin is a new potential therapeutic target to treat diabetes."
For more information on this research see: Hypothalamic Apelin/Reactive Oxygen Species Signaling Controls Hepatic Glucose Metabolism in the Onset of Diabetes. Antioxidants & Redox Signaling, 2014;20(4):557-573. Antioxidants & Redox Signaling can be contacted at: Mary Ann Liebert, Inc, 140 Huguenot Street, 3RD Fl, New Rochelle, NY 10801, USA. (Mary Ann Liebert, Inc. - www.liebertpub.com; Antioxidants & Redox Signaling - www.liebertpub.com/overview/antioxidants-and-redox-signaling/4/)
Our news correspondents report that additional information may be obtained by contacting A. Drougard, Univ Lille Nord France, Equipe Denutr Maternelles Perinatales, IFR 114, Unite Environm Perinatal & CroissanceEA 4489, Villeneuve Dascq, France. Additional authors for this research include T. Duparc, X. Brenachot, L. Carneiro, A. Gouaze, A. Fournel, L. Geurts, T. Cadoudal, A.C. Prats, L. Penicaud, D. Vieau, J. Lesage, C. Leloup, A. Benani, P.D. Cani, P. Valet and C. Knauf (see also Diabetes).
Keywords for this news article include: Biotechnology, France, Europe, Diabetes, Chalcogens, Metabolism, Gene Therapy, Endocrinology, Bioengineering, Oxygen Compounds, Villeneuve d'Ascq, Reactive Oxygen Species
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC